NASDAQ: KA - Kineta, Inc.

Lønnsomhet i seks måneder: -18.63%
Sektor: Healthcare

Kampanjeplan Kineta, Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet

Kineta, Inc., a clinical-stage biotechnology company, develops immunotherapies in the field of immuno-oncology, cancer, neurology, and arenaviruses. The company is developing KVA12123, an anti-VISTA antagonist mAb immunotherapy, which is in Phase 1/2 clinical trials for the treatment of solid tumors, including non-small cell lung cancer, ovarian cancer, colorectal cancer, colon cancer, pancreatic cancer, and gastric cancer.

flere detaljer
It is also developing anti-CD27 agonist mAb immunotherapy, which is in Phase 1 clinical trials for the treatment of advanced solid tumors, such as renal cell carcinoma, ovarian cancer, and colorectal cancer. In addition, the company develops immunotherapies for pain management and anti-viral therapy for the treatment of emerging diseases. Kineta, Inc. has collaboration and license agreements with MSD International Business GmbH, and GigaGen, Inc. The company was formerly known as Lecura, Inc. Kineta, Inc. was founded in 2007 and is headquartered in Seattle, Washington.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

EBITDA -0.0597
EV/EBITDA -1.78
IPO date 2016-02-11
ISIN US49461C1027
Industry Biotechnology
P/BV 1.89
P/S 23.63
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 0.005
Див.доход ао 0
Дивиденд ао 10.01
Сайт https://kinetabio.com
Цена ао 0.5521
Число акций ао 0.01105 млрд
Prisendring per dag: 0% (0.4801)
Prisendring per uke: 0% (0.4801)
Prisendring per måned: 0% (0.4801)
Prisendring over 3 måneder: -14.27% (0.56)
Prisendring over seks måneder: -18.63% (0.59)
Prisendring per år: -86.77% (3.63)
Prisendring over 3 år: -85.09% (3.22)
Prisendring over 5 år: -74.6% (1.89)
Prisendring over 10 år: 0% (0.4801)
Prisendring siden begynnelsen av året: 0% (0.4801)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 8.12 1
P/BV 14.45 1
P/E 0 0
EV/EBITDA -2.52 0
Total: 4

Effektivitet

Navn Betydning Karakter
ROA, % -137.14 0
ROE, % -487.85 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0.5 5
Total: 2.35

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.0838 10
Total: 10

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 8.84 2
Lønnsomhet Ebitda, % -73.68 0
Lønnsomhet EPS, % -99.21 0
Total: 0.4
Flere detaljer

Institusjoner Volum Dele, %
Armistice Capital, LLC 825792 7.53
Vanguard Group Inc 151380 1.38
FMR, LLC 123719 1.13
Geode Capital Management, LLC 50584 0.46
Northern Trust Corporation 36880 0.34
Stifel Financial Corporation 21853 0.2
Financial Advocates Investment Management 21744 0.2
Blackrock Inc. 19957 0.18
Renaissance Technologies, LLC 19044 0.17
ELEMENT POINTE ADVISORS, LLC 17696 0.16



Veileder Stillingstittel Betaling Fødselsår
Mr. Craig W. Philips President & Secretary 541.67k 1961 (64 år)
Ms. Pauline Kenny Esq., J.D. Advisor 349.72k 1974 (51 år)
Mr. Keith A. Baker Chief Financial Officer 485.75k 1967 (58 år)
Dr. Thierry Guillaudeux Ph.D. Chief Scientific Officer N/A 1968 (57 år)
Mr. Gary Gentges Executive Vice President of Corporate Development

Adresse: United States, Seattle. WA, 219 Terry Ave. N - åpne i Google maps, åpne Yandex-kart
Nettsted: https://kinetabio.com